C1QTNF9 and pulmonary arterial hypertension: However, following shunt placement, PAH rats treated with CTRP9 vector demonstrated significantly increased levels of phosphorylated AKT, p38-MAPK, and ERK, indicating that CTRP9 protected against PAH by activating the AKT pathway (Figures 5(a) and 5(b)).